A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus

NCT07751848 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

417

Enrollment

INDUSTRY

Sponsor class

Conditions

Lupus Erythematosus, Systemic

Interventions

DRUG: Anifrolumab

Sponsor

AstraZeneca